The Spanish Agency of Medicines and Health Products has issued a warning about a drug used to treat uterine fibroids. It recommends no new treatments using Esmya should begin until the drug is re-evaluated following reports of several serious cases of liver damage. The Agency says liver functions should be monitored every month in existing patients, and between two and four weeks after treatment ends.
COSTA DEL SOL NEWS
‘Robin Hood’ government slammed by the banks
Big banks and electricity giants are registering record profits – but are still up in arms over additional taxation imposed by the government to...
